30 closest matches · ranked by relevance
Antithrombin III Deficiency
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Venous Thrombosis (DVT) — 0 Participants
Antithrombin Deficiency, Congenital
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Vein Thrombosis (DVT). — 1 participants
ATIII Deficiency
Primary: Difference in the Mean and Standard Deviation (SD) of the Calibrated Automated Thrombography (CAT) Measurements of the Control and ATIII Groups at Time 5 (on Arrival in…
Acquired Antithrombin III Deficiency · Coronary Artery Bypass
Primary: Postoperative ATIII Levels at the ICU Admission — 94.06; 64.70 IU — p=<0.0001
Cardiac Surgery · Cardiopulmonary Bypass
Primary: Percentage of Subjects With Any Component of a Major Morbidity Composite — 68; 58 Participants
Traumatic Injury · Venous Thromboembolism
Primary: Initial AT-III Activity -- Control Group vs. Intervention Group Prior to Randomization — 87; 82 Percent AT-III activity (%) — p=0.092
Hemophilia · Factor XIII Deficiency
Primary: Response to Treatment of Bleeding Events Requiring Additional Factor XIII Infusions — 30; 1; 0; 3 Number of bleeds
Factor XIII Deficiency
Primary: Peak FXIII Concentration at Steady State — 0.9 Units/mL
Factor XIII Deficiency
Primary: The Incidence of Spontaneous Bleeding Events Requiring Treatment (Treatment is Defined as Administration of a FXIII-Containing Product to Treat the Bleeding Event) — 0…
Factor XIII Deficiency
Primary: Adverse Events — 42; 2; 2 participants
Heparin-induced Thrombocytopenia Type II
Primary: Composite of All-cause Death, Thrombosis (New and Extended) and Unplanned Amputation — 10 participants
Congenital Bleeding Disorder · Congenital FXIII Deficiency
Primary: Rate (Number Per Subject Year) of Bleeding Episodes Requiring Treatment With a FXIII Containing Product During the Treatment Period — 0.138 bleeding episodes per subject…
Congenital Bleeding Disorder · Congenital FXIII Deficiency
Primary: Area Under the Concentration vs. Time Curve (AUC) — 250.25 IU*h/mL
Type 3 Von Willebrand's Disease
Primary: Centralized Factor VIII (FVIII) Procoagulant Activity (FVIII:C) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis — 2.42 IU/dL
Acquired Thrombotic Thrombocytopenic Purpura
Primary: Time to Platelet Count Response — 2.69; 2.88 days — p== 0.0099
Congenital Bleeding Disorder · Congenital FXIII Deficiency
Primary: Adverse Events (AEs)(Serious and Non-serious) — 920; 19; 901 Events
Hemophilia A · Hemophilia B
Primary: Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period — 30.991; 3.133 episodes per participant per year — p=<0.0001
Alloimmune Thrombocytopenia · Fetal Alloimmune Thrombocytopenia
Primary: Number of Newborns With a Birth Platelet Count > 50,000/uL — 48; 47 number of newborns with >50,000 pets
Hemophilia A · Hemophilia B
Primary: Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period — 18.071; 1.666 episodes per participant per year — p=<0.0001
Thrombocytopenia
Primary: Bleeding Within 30 Days — 73; 78 Participants
Thrombotic Thrombocytopenic Purpura (TTP)
Primary: Number of Participants With Acute Thrombotic Thrombocytopenic Purpura (TTP) Events During Prophylactic Treatment — 0; 0; 1 Participants
COVID-19
Primary: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days. — 37; 52 Participants
Preeclampsia
Primary: Increase in Gestational Age in Days — 5.0; 6.0 days
Hemophilia A
Primary: To Assess the Immunogenicity of Plasma Derived VWF/FVIII and rFVIII Concentrates by Determining the Frequency of Inhibitor Development in the First 50 EDs or in the…
Congenital Afibrinogenemia · Congenital Hypofibrinogenemia
Primary: Single-dose Pharmacokinetics (PK) of BT524: Terminal Elimination Half-life (t1/2) for Fibrinogen Antigen — 67.9 hours
Blood Loss, Surgical
Primary: Number or Participants With Antirecombinant Thrombin (rThrombin) Product Antibody at Baseline and Day 29 — 0; 0 Participants
Acute HIT II (Heparin-induced Thrombocytopenia Type II)
Primary: Number of Participants Diagnosed With Thrombosis and/or Pulmonary Embolism After the Occurrence of HIT II — 31; 4; 45; 78 participants
Thrombotic Microangiopathies
Primary: Percent of Total Doses of Defibrotide That Were Missed [Feasibility] — 0.7 percentage of missed doses
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
Congenital Bleeding Disorder · Congenital FXIII Deficiency
Primary: Number of Treatment Emergent (Serious and Non-serious) Adverse Events — 100; 2; 98 number of events